https://www.selleckchem.com/products/crcd2.html
8%). Only four patients (19.04%) received alendronate, while intravenous bisphosphonates, such as zoledronate and pamidronate, represented the treatment of most of our sample. Most of our patients presented stage 1 and 2 MRONJ (85.7%), whose lesions were mainly observed in the mandible (52.4%). Fifty-seven percent of the patients had at least one bone change. Conclusions In BRONJ, bone changes vary between exposed and non-exposed areas and one aspect of the study was persistent extraction cavities in the BRONJ lesion region and high frequ
Curtir
Comentario
Compartilhar
